Compare Stocks: PBH, XNCR, and KRTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRTX Karuna Therapeutics	$329.83	$327.01	$158.38 ▼ $329.99	$12.58B	1.18	832,048 shs	N/A
PBH Prestige Consumer Healthcare	$47.40 -2.7%	$50.86	$42.62 ▼ $71.07	$2.25B	0.33	553,095 shs	513,590 shs
XNCR Xencor	$24.26 -2.7%	$21.66	$8.26 ▼ $30.61	$1.80B	0.88	916,697 shs	1.36 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRTX Karuna Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
PBH Prestige Consumer Healthcare	-2.39%	-8.13%	-7.93%	+2.00%	-26.33%
XNCR Xencor	-1.54%	-7.29%	+15.57%	+106.29%	+200.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRTX Karuna Therapeutics	$329.83	$327.01	$158.38 ▼ $329.99	$12.58B	1.18	832,048 shs	N/A
PBH Prestige Consumer Healthcare	$47.40 -2.7%	$50.86	$42.62 ▼ $71.07	$2.25B	0.33	553,095 shs	513,590 shs
XNCR Xencor	$24.26 -2.7%	$21.66	$8.26 ▼ $30.61	$1.80B	0.88	916,697 shs	1.36 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRTX Karuna Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
PBH Prestige Consumer Healthcare	-2.39%	-8.13%	-7.93%	+2.00%	-26.33%
XNCR Xencor	-1.54%	-7.29%	+15.57%	+106.29%	+200.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KRTX Karuna Therapeutics	0.00	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	2.17	Hold	$70.75	49.28% Upside
XNCR Xencor	2.67	Moderate Buy	$30.71	26.60% Upside

Current Analyst Ratings Breakdown

Latest PBH, XNCR, and KRTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	XNCR Xencor	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$14.00 ➝ $21.00
9/1/2026	XNCR Xencor	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Strong-Buy	$40.00 ➝ $46.00
8/10/2026	PBH Prestige Consumer Healthcare	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/6/2026	XNCR Xencor	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$19.00 ➝ $20.00
8/6/2026	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$26.00 ➝ $30.00
8/6/2026	XNCR Xencor	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$43.00 ➝ $44.00
7/30/2026	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$26.00
7/7/2026	XNCR Xencor	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$29.00 ➝ $27.00
7/6/2026	XNCR Xencor	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
6/25/2026	PBH Prestige Consumer Healthcare	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
6/24/2026	XNCR Xencor	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KRTX Karuna Therapeutics	$654K	19,239.07	N/A	N/A	$33.24 per share	9.92
PBH Prestige Consumer Healthcare	$1.10B	2.03	$4.96 per share	9.56	$39.89 per share	1.19
XNCR Xencor	$125.58M	14.36	N/A	N/A	$8.90 per share	2.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KRTX Karuna Therapeutics	-$433.68M	-$11.72	N/A	N/A	N/A	N/A	-31.63%	-30.38%	N/A
PBH Prestige Consumer Healthcare	$190.30M	$3.57	13.28	9.31	1.56	15.57%	11.39%	5.66%	11/5/2026 (Estimated)
XNCR Xencor	-$91.92M	-$2.17	N/A	N/A	N/A	-155.59%	-28.66%	-20.38%	11/4/2026 (Estimated)

Latest PBH, XNCR, and KRTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2026	Q1 2027	PBH Prestige Consumer Healthcare	$0.8940	$0.98	+$0.0860	$0.61	$253.02 million	$265.71 million
8/5/2026	Q2 2026	XNCR Xencor	-$0.8015	-$0.29	+$0.5115	-$0.29	$18.89 million	$51.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KRTX Karuna Therapeutics	N/A	N/A	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	$1.90	4.01%	N/A	53.22%	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KRTX Karuna Therapeutics	N/A	19.31	19.31
PBH Prestige Consumer Healthcare	1.06	3.23	1.99
XNCR Xencor	N/A	6.39	6.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KRTX Karuna Therapeutics	N/A
PBH Prestige Consumer Healthcare	99.95%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
KRTX Karuna Therapeutics	13.20%
PBH Prestige Consumer Healthcare	1.50%
XNCR Xencor	5.08%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KRTX Karuna Therapeutics	339	38.15 million	33.16 million	Optionable
PBH Prestige Consumer Healthcare	540	47.38 million	46.66 million	Optionable
XNCR Xencor	280	74.35 million	70.58 million	Optionable

PBH, XNCR, and KRTX Headlines

Recent News About These Companies

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 260,752 Shares of Xencor, Inc. $XNCR

September 9 at 4:55 AM | marketbeat.com

The Manufacturers Life Insurance Company Buys Shares of 49,696 Xencor, Inc. $XNCR

September 6, 2026 | marketbeat.com

Seven Fleet Capital Management LP Has $5.93 Million Stake in Xencor, Inc. $XNCR

September 5, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

September 5, 2026 | americanbankingnews.com

Man Group plc Takes Position in Xencor, Inc. $XNCR

September 4, 2026 | marketbeat.com

Bank of New York Mellon Corp Makes New Investment in Xencor, Inc. $XNCR

September 4, 2026 | marketbeat.com

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Xencor (NASDAQ:XNCR) Stock

September 3, 2026 | marketbeat.com

Xencor to Present at the 2026 Cantor Global Healthcare Conference

September 2, 2026 | finance.yahoo.com

Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of "Hold" from Analysts

September 1, 2026 | americanbankingnews.com

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Hold" by Brokerages

September 1, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Sees Large Volume Increase - Here's What Happened

August 31, 2026 | marketbeat.com

Hsbc Holdings PLC Buys Shares of 125,482 Xencor, Inc. $XNCR

August 31, 2026 | marketbeat.com

Legal & General Group Plc Acquires Shares of 1,091,177 Xencor, Inc. $XNCR

August 31, 2026 | marketbeat.com

Deutsche Bank AG Acquires New Shares in Xencor, Inc. $XNCR

August 29, 2026 | marketbeat.com

Bank of America Corp DE Sells 263,315 Shares of Xencor, Inc. $XNCR

August 29, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Stock Price Down 9% - What's Next?

August 28, 2026 | marketbeat.com

Jefferies Financial Group Inc. Takes Position in Xencor, Inc. $XNCR

August 28, 2026 | marketbeat.com

BlackRock Inc. Buys Shares of 13,651,261 Xencor, Inc. $XNCR

August 28, 2026 | marketbeat.com

368,305 Shares in Xencor, Inc. $XNCR Bought by Seven Fleet Capital Management LP

August 27, 2026 | marketbeat.com

Primecap Management Co. CA Invests $163.92 Million in Xencor, Inc. $XNCR

August 26, 2026 | marketbeat.com

ADAR1 Capital Management LLC Invests $3.74 Million in Xencor, Inc. $XNCR

August 26, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBH, XNCR, and KRTX Company Descriptions

Karuna Therapeutics NASDAQ:KRTX

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Prestige Consumer Healthcare NYSE:PBH

$47.40 -1.31 (-2.68%)

Closing price 03:59 PM Eastern

Extended Trading

$47.36 -0.04 (-0.08%)

As of 07:30 PM Eastern

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Xencor NASDAQ:XNCR

$24.26 -0.68 (-2.73%)

Closing price 04:00 PM Eastern

Extended Trading

$24.28 +0.02 (+0.10%)

As of 07:30 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PBH, XNCR, and KRTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PBH, XNCR, and KRTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PBH, XNCR, and KRTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBH, XNCR, and KRTX Company Descriptions

Karuna Therapeutics NASDAQ:KRTX

Prestige Consumer Healthcare NYSE:PBH

Xencor NASDAQ:XNCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PBH, XNCR, and KRTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PBH, XNCR, and KRTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PBH, XNCR, and KRTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBH, XNCR, and KRTX Company Descriptions

Karuna Therapeutics NASDAQ:KRTX

Prestige Consumer Healthcare NYSE:PBH

Xencor NASDAQ:XNCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools